SAN FRANCISCO, California — A small, phase 2 study, with a biomarker test for its primary end point, offers some encouraging hints that the P-selectin antagonist inclacumab may be able to reduce ...

Acute coronary syndrome (ACS) in younger patients presents distinctive epidemiological and clinical patterns when compared with older cohorts. Although traditionally viewed as a disease of older ...

The American College of Cardiology and the American Heart Association today released an updated clinical practice guideline for managing individuals experiencing acute coronary syndrome (ACS). The ...

The conventional classification of acute myocardial infarction (AMI) into ST-segment elevation (STEMI) and non-ST-segment elevation (NSTEMI) has long guided clinical decision-making. However, emerging ...

A recent opinion paper concluded that timely revascularization and dual antiplatelet therapy (DAPT) are crucial in the ...

PARIS, France—Among patients with acute MI and occlusive disease on invasive angiography, those presenting without ST-segment elevation on the initial ECG fare worse than those with STEMI, researchers ...

Patients who received an implantable heart rhythm monitor after suffering a heart attack did not have fewer subsequent cardiovascular events overall, but a subset of patients whose heart attack was ...

Lower risk for bleeding without increase in ischemic events seen for patients with acute coronary syndrome. HealthDay News — For patients with acute coronary syndrome (ACS) undergoing drug-eluting ...

The diagnostics advisory committee considered evidence on high-sensitivity troponin tests for the early rule out of non-ST-segment elevation myocardial infarction (NSTEMI) from several sources. Full ...

Medical Management/Treatment Initial treatment for suspected STEMI and NSTEMI requires a loading dose of nonenteric coated ASA at 162 to 325 mg (unless contraindicated), nitroglycerin in response to ...

An invasive strategy vs. optimal medical therapy alone after a non-ST-elevation myocardial infarction (NSTEMI) in older adults did not affect the combined risk of cardiovascular death or MI, although ...